Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016
27 October 2016 - 11:30PM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
third quarter of 2016 on Thursday, November 3, 2016. The
Company will host a webcast and conference call that day at 8:30
a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for
domestic callers or (765) 507-2618 for international callers and
referring to conference ID number 90389179. A live webcast of
the conference call will be available online in the Investors and
Media section of the Company’s website
at ir.minervaneurosciences.com. The archived webcast will be
available on the Company’s website beginning approximately two
hours after the event for 30 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
which has completed a Phase IIb clinical trial for schizophrenia;
MIN-117, which has completed a Phase IIa clinical trial development
for MDD; MIN-202 (JNJ-42847922), which has completed Phase
IIa and Phase Ib clinical trials for insomnia and MDD,
respectively; and MIN-301, in pre-clinical development for
Parkinson’s disease. Minerva’s common stock is listed on the
NASDAQ Global Market under the symbol “NERV.” For more
information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024